Corventum

1 known investors

Corventum is a biopharmaceutical company developing therapies that protect the heart from the toxic effects of cancer treatment, allowing patients to continue first-line oncology therapy. Its lead program, CVT-130, is a small molecule for the prevention of anthracycline cardiotoxicity, advancing into the clinic in 2026.

BiotechMedical Devices